Mixed micelles loaded with the 5-benzylidenethiazolidine-2,4-dione derivative SKLB023 for efficient treatment of non-alcoholic steatohepatitis

Background: SKLB023, a novel 5-benzylidenethiazolidine-2,4-dione based-derivative, specifically inhibits inducible nitric oxide synthase and shows promise for treating non-alcoholic steatohepatitis (NASH). However, its poor water solubility and low bioavailability limits its clinical use. Here the drug was loaded into phosphatidylcholine-bile salt-mixed micelles (PBMM/SKLB023) to overcome these limitations. Methods: PBMM/SKLB023 was developed using a simple co-precipitation method, and formulation parameters were optimized. The pharmacokinetics of PBMM/SKLB023 were investigated in Wistar rats, and therapeutic efficacy was assessed in a mouse model of NASH induced by a diet deficient in methionine- and choline. Results: PBMM/SKLB023 particles were 11.36±2.08 nm based on dynamic light scattering, and loading the drug into micelles improved its water solubility 300-fold. PBMM/SKLB023 inhibited proliferation and activation of HSC-T6 cells more strongly than free SKLB023. PBMM/SKLB023 showed longer mean retention time and higher bioavailability than the free drug after intravenous injection in Wistar rats. In the mouse model of NASH, PBMM/SKLB023 alleviated hepatic lipid accumulation, inflammation, and fibrosis to a significantly greater extent than free SKLB023. Conclusion: PBMM/SKLB023 shows therapeutic potential for treating NASH and liver fibrosis.

• Publication year

  2019

• Venue

  International Journal of Nanomedicine

• Publication date

  2019-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2147/IJN.S202821PMID 31239664PMCID 6551597
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nanocarriers as an Emerging Platform for Cancer Therapy

  2020cited by this paper
• Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

  2019cited by this paper
• Non-alcoholic fatty liver disease - A global public health perspective.

  2019cited by this paper
• SKLB023 hinders renal interstitial fibrosis in obstructive nephropathy by interfering TGF-β1/Smad3 signaling

  2018cited by this paper
• SKLB023 as an iNOS inhibitor alleviated liver fibrosis by inhibiting the TGF-beta/Smad signaling pathway

  2018cited by this paper
• Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis.

  2018cited by this paper
• Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?

  2018cited by this paper
• Hepatic stellate cells as key target in liver fibrosis.

  2017cited by this paper
• Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present.

  2017cited by this paper
• Mechanisms of hepatic stellate cell activation

  2017cited by this paper
• Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis

  2017cited by this paper
• Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease

  2016cited by this paper
• Comparison of bile salt/phosphatidylcholine mixed micelles in solubilization to sterols and stability

  2016cited by this paper
• Promising therapies for treatment of nonalcoholic steatohepatitis

  2016cited by this paper
• Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

  2015cited by this paper
• Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase

  2015cited by this paper
• Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options

  2015cited by this paper
• The role of iNOS in cholesterol-induced liver fibrosis

  2015cited by this paper
• Specific hepatic delivery of procollagen α1(I) small interfering RNA in lipid‐like nanoparticles resolves liver fibrosis

  2015cited by this paper
• The global burden of liver disease: a challenge for methods and for public health

  2014cited by this paper
• Liposomal Oxymatrine in Hepatic Fibrosis Treatment: Formulation, In Vitro and In Vivo Assessment

  2014cited by this paper
• SKLB023 Blocks Joint Inflammation and Cartilage Destruction in Arthritis Models via Suppression of Nuclear Factor-Kappa B Activation in Macrophage

  2013cited by this paper
• PPARs: history and advances.

  2013cited by this paper
• Activation of the Aryl Hydrocarbon Receptor Sensitizes Mice to Nonalcoholic Steatohepatitis by Deactivating Mitochondrial Sirtuin Deacetylase Sirt3

  2013cited by this paper
• Nimodipine-loaded mixed micelles: formulation, compatibility, pharmacokinetics, and vascular irritability study

  2012cited by this paper
• Mixed micelles loaded with silybin-polyene phosphatidylcholine complex improve drug solubility

  2011cited by this paper
• Synthesis and biological evaluation of novel 5-benzylidenethiazolidine-2,4-dione derivatives for the treatment of inflammatory diseases.

  2011cited by this paper
• Novel treatment modalities for nonalcoholic steatohepatitis.

  2010cited by this paper
• [Model of experimental nonalcoholic steatohepatitis from use of methionine and choline deficient diet].

  2009cited by this paper
• Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis.

  2008cited by this paper
• Lack of inducible nitric oxide synthase leads to increased hepatic apoptosis and decreased fibrosis in mice after chronic carbon tetrachloride administration

  2008cited by this paper
• Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice.

  2008cited by this paper
• Nanocarriers as an emerging platform for cancer therapy.

  2007cited by this paper
• Pioglitazone: the beginning of a new era for NASH?

  2007cited by this paper
• The peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, l-amino acid-defined diet.

  2005cited by this paper
• The influence of bile salts and mixed micelles on the pharmacokinetics of quinine in rabbits.

  2005cited by this paper
• Increasing drug solubility by means of bile salt-phosphatidylcholine-based mixed micelles.

  1998cited by this paper
• Solubility and stability of tetrazepam in mixed micelles.

  1998cited by this paper
• Preclinical safety evaluation of intravenously administered mixed micelles.

  1984cited by this paper

• Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights

  2025cites this paper
• Nanoformulations for the Diagnosis and Treatment of Metabolic Dysfunction-associated Steatohepatitis.

  2024cites this paper
• Nano-drug delivery systems (NDDS) in metabolic dysfunction-associated steatotic liver disease (MASLD): current status, prospects and challenges

  2024cites this paper
• Targeted Delivery of Celastrol via Chondroitin Sulfate Derived Hybrid Micelles for Alleviating Symptoms in Nonalcoholic Fatty Liver Disease.

  2023cites this paper
• Nanodrug delivery systems for metabolic chronic liver diseases: advances and perspectives.

  2023cites this paper
• Schisandrin B Promotes Hepatic Stellate Cell Ferroptosis via Wnt Pathway-Mediated Ly6Clo Macrophages.

  2023cites this paper
• Biocompatible phospholipid-based mixed micelles for posaconazole ocular delivery: Development, characterization, and in - vitro antifungal activity

  2022cites this paper
• Potentialities of nanomaterials for the management and treatment of metabolic syndrome: A new insight

  2022cites this paper
• The Emerging Role of Nanomedicine in the Management of Nonalcoholic Fatty Liver Disease: A State-of-the-Art Review

  2021cites this paper